226 related articles for article (PubMed ID: 10554098)
1. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.
Gulyaev AE; Gelperina SE; Skidan IN; Antropov AS; Kivman GY; Kreuter J
Pharm Res; 1999 Oct; 16(10):1564-9. PubMed ID: 10554098
[TBL] [Abstract][Full Text] [Related]
2. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats.
Ambruosi A; Yamamoto H; Kreuter J
J Drug Target; 2005 Dec; 13(10):535-42. PubMed ID: 16390814
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
Ambruosi A; Khalansky AS; Yamamoto H; Gelperina SE; Begley DJ; Kreuter J
J Drug Target; 2006 Feb; 14(2):97-105. PubMed ID: 16608736
[TBL] [Abstract][Full Text] [Related]
4. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
Ambruosi A; Gelperina S; Khalansky A; Tanski S; Theisen A; Kreuter J
J Microencapsul; 2006 Aug; 23(5):582-92. PubMed ID: 16980278
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
6. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
Gelperina SE; Khalansky AS; Skidan IN; Smirnova ZS; Bobruskin AI; Severin SE; Turowski B; Zanella FE; Kreuter J
Toxicol Lett; 2002 Jan; 126(2):131-41. PubMed ID: 11751017
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques.
Reddy LH; Murthy RS
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Dec; 148(2):161-6. PubMed ID: 15744366
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumour.
Reddy LH; Sharma RK; Murthy RS
J Drug Target; 2004; 12(7):443-51. PubMed ID: 15621669
[TBL] [Abstract][Full Text] [Related]
10. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Kreuter J; Gelperina S
Toxicol Lett; 2008 Apr; 178(1):9-19. PubMed ID: 18374523
[TBL] [Abstract][Full Text] [Related]
11. Use of nanoparticles for cerebral cancer.
Kreuter J; Gelperina S
Tumori; 2008; 94(2):271-7. PubMed ID: 18564616
[TBL] [Abstract][Full Text] [Related]
12. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
Petri B; Bootz A; Khalansky A; Hekmatara T; Müller R; Uhl R; Kreuter J; Gelperina S
J Control Release; 2007 Jan; 117(1):51-8. PubMed ID: 17150277
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting.
Bragagni M; Mennini N; Ghelardini C; Mura P
J Pharm Pharm Sci; 2012; 15(1):184-96. PubMed ID: 22365096
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
16. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Gao K; Jiang X
Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.
De Juan BS; Von Briesen H; Gelperina SE; Kreuter J
J Drug Target; 2006 Nov; 14(9):614-22. PubMed ID: 17090397
[TBL] [Abstract][Full Text] [Related]
18. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).
Kreuter J; Alyautdin RN; Kharkevich DA; Ivanov AA
Brain Res; 1995 Mar; 674(1):171-4. PubMed ID: 7773690
[TBL] [Abstract][Full Text] [Related]
19. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
[TBL] [Abstract][Full Text] [Related]
20. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
